Xiaomeng Dai

Xiaomeng Dai

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2024 in Advanced Science
Verified
Journal Article
Open access
PDF file
CLChuan Liu
Chuan Liu
JXJindong Xie
Jindong Xie
BLBo Lin
Bo Lin
WTWeihong Tian
Weihong Tian
YWYifan Wu
Yifan Wu
PZPeng Zhao
Peng Zhao
The heterogeneity of macrophages influences the response to immune checkpoint inhibitor (ICI) therapy. However, few studies explore the impact of APOE + macrophages on ICI therapy using single‐cell RNA sequencing (scRNA‐seq) and machine learning methods. The scRNA‐seq and bulk RNA‐seq data are Integrated to construct an M.Sig model for predicting ICI response based on the distinct molecular signatures of macrophage and machine learning algorithms. Comprehensive single‐cell analysis as well as in vivo and in vitro experiments are applied to explore the potential mechanisms of the APOE + macrophage in affecting ICI response. The M.Sig model shows clear advantages in predicting the efficacy and prognosis of ICI therapy in pan‐cancer patients. The proportion of APOE + macrophages is higher in ICI non‐responders of triple‐negative breast cancer compared with responders, and the interaction and longer distance between APOE + macrophages and CD8 + exhausted T (Tex) cells affecting ICI response is confirmed by multiplex immunohistochemistry. In a 4T1 tumor‐bearing mice model, the APOE inhibitor combined with ICI treatment shows the best efficacy. The M.Sig model using real‐world immunotherapy data accurately predicts the ICI response of pan‐cancer, which may be associated with the interaction between APOE + macrophages and CD8 + Tex cells.

6 January 2024 in Biomaterials
Verified
Journal Article
Closed access
YJYuzhi Jin
Yuzhi Jin
YHYangyue Huang
Yangyue Huang
HRHui Ren
Hui Ren
HHHuanhuan Huang
Huanhuan Huang
CLChunyu Lai
Chunyu Lai
XDXiaomeng Dai
Xiaomeng Dai

5 January 2017 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
Dejun ZhangDejun Zhang
Dejun Zhang
LZLei Zhao
Lei Zhao
PZpengfei zhou
pengfei zhou
HMHong Ma
Hong Ma
FHFang Huang
Fang Huang
TZTao Zhang
Tao Zhang
Circulating tumor cells (CTCs) detected in peripheral blood (PB) of cancer patients can be identified as isolated CTCs and circulating tumor microemboli (CTM). This study aimed to evaluate the prognostic value of CTM detection and CTC phenotype in advanced colorectal cancer (CRC) patients during chemotherapy. A size-based platform for CTC isolation was applied. PB samples (5 ml) from 98 advanced CRC patients during 2–6 cycles chemotherapy were collected for CTC detection, and CTC count was correlated to patient’s clinicopathological characteristics and clinical outcome. And CTC phenotype was measured by immunofluorescent staining and evaluate the predictive significance on survival in 32 CTCs-positive patients with advanced CRC. Forty-eight of 98 patients were CTCs-positive, including 18 CTM-positive patients, and CTC detection was positively correlated with lymphatic invasion (P = 0.049), TNM stage (P = 0.023), and serum CEA level (P = 0.014). Moreover, Kaplan–Meier survival and Cox regression analyses revealed that the presence of CTCs was an independent factor for poor PFS and OS (P < 0.05) in advanced CRC patients during chemotherapy, and CTM-positive patients had shooter survival than isolated CTCs-positive patients (P < 0.05). Furthermore, patients with vimentin+ isolated CTCs/CTM had shorter PFS and OS compared with CK+ CTCs (P < 0.05). This study provided evidence that the presence of CTCs was positively correlated with poor prognosis, and furthermore, CTM and vimentin+ CTCs predicted poorer survival, which indicated that CTM and vimentin+ CTCs detected by a sensitive platform could be used to improve prognostic value of CTCs in advanced CRC patients under treatment.

20 May 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
XBXuanwen Bao
Xuanwen Bao
QLQiong Li
Qiong Li
JCJinzhang Chen
Jinzhang Chen
DCDiyu Chen
Diyu Chen
CYChanqi Ye
Chanqi Ye
Jian RuanJian Ruan
Jian Ruan
Intrahepatic cholangiocarcinoma (ICC) is a relatively rare but highly aggressive tumor type that responds poorly to chemotherapy and immunotherapy. Comprehensive molecular characterization of ICC is essential for the development of novel therapeutics. Here, we constructed two independent cohorts from two clinic centers. A comprehensive multiomics analysis of ICC via proteomic, whole-exome sequencing (WES), and single-cell RNA sequencing (scRNA-seq) was performed. Novel ICC tumor subtypes were derived in the training cohort (n = 110) using proteomic signatures and their associated activated pathways, which were further validated in a validation cohort (n = 41). Three molecular subtypes, chromatin remodeling, metabolism, and chronic inflammation, with distinct prognoses in ICC were identified. The chronic inflammation subtype was associated with a poor prognosis. Our random forest algorithm revealed that mutation of lysine methyltransferase 2D (KMT2D) frequently occurred in the metabolism subtype and was associated with lower inflammatory activity. scRNA-seq further identified an APOE+C1QB+ macrophage subtype, which showed the capacity to reshape the chronic inflammation subtype and contribute to a poor prognosis in ICC. Altogether, with single-cell transcriptome-assisted multiomics analysis, we identified novel molecular subtypes of ICC and validated APOE+C1QB+ tumor-associated macrophages as potential immunotherapy targets against ICC.

1 January 2017 in Disease Markers
Verified
Journal Article
Open access
PDF file
XDXiaomeng Dai
Xiaomeng Dai
THTao Huang
Tao Huang
SYSheng-li Yang
Sheng-li Yang
XZXiu-Mei Zheng
Xiu-Mei Zheng
GCGeorge G. Chen
George G. Chen
TZTao Zhang
Tao Zhang
Accumulating evidence suggests that the tumor microenvironment has a profound influence on tumor initiation and progression, opening a new avenue for studying tumor biology. Nonetheless, the prognostic values of the peritumoral expression of EpCAM and CD13 remain to be elucidated in hepatocellular carcinoma (HCC) patients. In this study, the expression of EpCAM and CD13 was assessed by immunohistochemistry in peritumoral liver hepatocytes from 106 hepatitis B virus- (HBV-) related HCC patients who had undergone curative hepatectomy. The peritumoral EpCAM-positive group had a significantly worse overall survival (OS) (p=0.003) and recurrence-free survival (RFS) (p=0.022) compared to the negative group. Peritumoral CD13-positive patients were also associated with poor OS (p=0.038), while not significantly associated with RFS. The adjusted multivariate COX proportional hazard regression analysis suggested that only the positive expression of peritumoral EpCAM precisely predicted poor OS. Being peritumoral EpCAM positive was also significantly associated with a larger tumor size, liver cirrhosis, and more frequent vascular invasion; however, no statistically significant association was observed between CD13 and any clinicopathological features. Taken together, peritumoral EpCAM and CD13 expression was associated with a poor prognosis, but EpCAM may be a better prognostic marker than CD13 in HBV-related HCC patients. In the future, peritumoral EpCAM could be a good target for adjuvant therapy after curative hepatectomy.

22 July 2022 in International Journal of Computer Assisted Radiology and Surgery
Verified
Journal Article
Closed access
PDF file
HZHangyu Zhang
Hangyu Zhang
XZXudong Zhu
Xudong Zhu
BLBin Li
Bin Li
XDXiaomeng Dai
Xiaomeng Dai
XBXuanwen Bao
Xuanwen Bao
XJXinyu Jin
Xinyu Jin